NTIC

Business Context and Reporting Period

Company: Northern Technologies International Corp (NTIC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: February 28, 2009
Business Overview: NTIC develops and markets proprietary environmentally beneficial products, primarily corrosion prevention (ZERUST®), and emerging businesses including bioplastics (Natur-Tec®) and plastic-to-fuel technology. The company operates through direct sales and a network of 29 corporate joint ventures globally.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: North American net sales decreased 19.9% year-over-year, driven by a 23.0% drop in ZERUST® sales due to the global economic recession and the automotive industry downturn. This was partially offset by a 372.2% increase in Natur-Tec® sales.
• Impairment Charge: A non-cash loss on impairment of $554,000 was recorded for the React-NTI reporting unit due to the cessation of ink additive sales and the decision to halt further product development for SERAVAT® and Farona®.
• Profitability Shift: The company swung from a net income of $1.32 million in the prior year to a net loss of $1.50 million. This was primarily caused by reduced sales volume, the impairment charge, and a 64.8% decrease in equity income from corporate joint ventures.
• Cost Structure: Cost of goods sold as a percentage of net sales increased to 68.9% (from 59.3%) due to the higher proportion of lower-margin Natur-Tec® sales. However, operating expenses were reduced through salary cuts, hiring freezes, and layoffs affecting 16% of the workforce.
• Debt Utilization: Borrowings under the $2.3 million line of credit increased to $599,000 from $86,000 to manage liquidity.

Guidance, Outlook, and Risks

• Outlook: Management expects operating results from the core ZERUST® business to improve in the third fiscal quarter of 2009 as cost-cutting measures take full effect. Natur-Tec® sales are not expected to increase significantly until the end of the third or beginning of the fourth quarter due to distributor challenges.
• R&D Investment: NTIC anticipates spending between $2.8 million and $3.0 million on research and development for new technologies during fiscal 2009.
• Liquidity: The company believes existing cash, forecasted cash flows, and joint venture distributions will be sufficient to fund operations for the next 12 months. Additional financing may be sought to expand emerging businesses.
• Key Risks:
  • Continued adverse effects of the global economic recession and the automotive industry downturn.
  • Dependence on the success and dividend distributions of corporate joint ventures.
  • Foreign currency exchange rate fluctuations affecting reported income.
  • Unresolved legal proceedings with Shamrock Technologies, Inc., though parties are currently at an impasse in mediation.

Investor Verification Checklist

• Impairment Details: Verify the valuation methodology used for the $554,000 React-NTI impairment and confirm the remaining net book value of the unit is effectively zero.
• Joint Venture Performance: Review the specific financial performance of the 29 joint ventures, as a 33.9% drop in their sales significantly impacts NTIC's fee income and equity earnings.
• Liquidity Position: Monitor the utilization of the $2.3 million line of credit and the company's ability to service debt while maintaining R&D spending.
• Legal Contingencies: Track the status of the Shamrock Technologies litigation and the potential for material adverse effects if mediation fails.
• Natur-Tec® Growth: Assess the recovery of the principal Natur-Tec® distributor and the timeline for projected sales growth in the bioplastics segment.